ZS Pharma Price Target Raised to $54.00 (ZSPH)
Stock analysts at Credit Suisse lifted their target price on shares of ZS Pharma (NASDAQ:ZSPH) from $51.00 to $54.00 in a report issued on Tuesday. Credit Suisse’s target price suggests a potential upside of 34.03% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at William Blair initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “outperform” rating and a $75.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “overweight” rating and a $43.00 price target on the stock. Finally, analysts at BMO Capital Markets initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “outperform” rating and a $38.00 price target on the stock.
ZS Pharma (NASDAQ:ZSPH) traded down 4.99% on Tuesday, hitting $38.28. The stock had a trading volume of 201,329 shares. ZS Pharma has a 52 week low of $25.51 and a 52 week high of $43.00. The stock’s 50-day moving average is $30.97 and its 200-day moving average is $30.16. The company’s market cap is $796.9 million. ZS Pharma also was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 680,843 shares, an increase of 24.4% from the July 31st total of 547,249 shares. Based on an average daily trading volume, of 55,071 shares, the short-interest ratio is presently 12.4 days. Approximately 8.2% of the shares of the company are short sold.
ZS Pharma (NASDAQ:ZSPH) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($4.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.66) by $4.06. On average, analysts predict that ZS Pharma will post $-4.03 earnings per share for the current fiscal year.
ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.